Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02042872 · ClinicalTrials.gov registry record · Phase 4
Zoledronic Acid Administration in Acute Spinal Cord Injury
A Phase 4 study, sponsored by James J. Peters Veterans Affairs Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT02042872 is a Phase 4 study that has completed, run by James J. Peters Veterans Affairs Medical Center. The registered enrollment target is 21 participants.
The verdict
NCT02042872, a Phase 4 study, has completed, sponsored by James J. Peters Veterans Affairs Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
In subjects with acute SCI: To compare the effects of parenteral zoledronic acid therapy on preservation of regional and total skeletal mass (DXA). Hypothesis: Zoledronic acid will dramatically diminish bone loss in persons with acute SCI, as evidenced by serial densitometry determinations (DXA).
Interventions
- DRUG Zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2006-05 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02042872
The ClinicalTrials.gov registry entry for NCT02042872 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James J. Peters Veterans Affairs Medical Center, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zoledronic acid is the first listed.
NCT02042872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02042872 about?
NCT02042872 is a clinical study titled "Zoledronic Acid Administration in Acute Spinal Cord Injury". In subjects with acute SCI: To compare the effects of parenteral zoledronic acid therapy on preservation of regional and total skeletal mass (DXA). Hypothesis: Zoledronic acid will dramatically diminish bone loss in persons with acute SCI, as evidenced by serial densitometry determinations (DXA).
What is the current status of trial NCT02042872?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2006-05. Estimated completion is 2012-07.
What interventions are being tested in trial NCT02042872?
The interventions under investigation include: Zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT02042872?
This trial is sponsored by James J. Peters Veterans Affairs Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.